Eptinezumab

Extended indication	Migraine profylaxe van 'frequent episodic migraine' (EM) en 'chronic migraine' (CM).
Therapeutic value	Possible added value
Total cost	120,000,000.00

Product

Active substance	Eptinezumab
Domain	Neurological disorders
Main indication	Headache
Extended indication	Migraine profylaxe van 'frequent episodic migraine' (EM) en 'chronic migraine' (CM).
Manufacturer	Alder
Route of administration	Intravenous
Therapeutical formulation	Intravenous drip
Budgetting framework	Intermural (MSZ)
Additional remarks	Werkingsmechanisme: 'Calcitonin gene-related peptide receptor (CGRPR) monoklonaal antilichaam'. Toelichtin indicatie: EM is 5-14 dagen migraine per maand en CM is 15+ dagen hoofpijn per maand waarvan in ieder geval 8 keer migraine.

Registration

Registration route	Centralised (EMA)
Orphan drug	No

Therapeutic value

Current treatment options	In ontwikkeling zijn andere GCRP antilichamen voor vergelijkbare indicatie: Erenumab, Galcanezumab, Fremanezumab. Huidige behandeling profylaxe: betablokkers, anticonvulsiva.
Therapeutic value	Possible added value
Substantiation	Mogelijke meerwaarde, bij die patiënten waarbij andere profylactische therapieën (zoals bijvoorbeeld betablokkers, anticonvulsiva, flunarizine) falen.
Duration of treatment	continuous
Frequency of administration	4 times a year
Dosage per administration	300 mg
References	clinicaltrials.gov: NCT02974153, NCT02985398. http://investor.alderbio.com/releasedetail.cfm?releaseid=1031418, http://investor.alderbio.com/releasedetail.cfm?ReleaseID=1039500.
Additional remarks	Toedieningsfrequentie: elke 12 weken.

Expected patient volume per year

Patient volume	8,000 - 24,000 Market share is generally not included unless otherwise stated.
Additional remarks	Patiëntenaantal gebasseerd op erenumab.

Patient volume

8,000 - 24,000

Market share is generally not included unless otherwise stated.

Additional remarks

Patiëntenaantal gebasseerd op erenumab.

Expected cost per patient per year

Cost	5,000.00 - 10,000.00
Additional remarks	Verwachting is dat het meerkosten gaat opleveren. Kosten waarschijnlijk hoog. Huidige standaardbehandeling (profylaxe) is goedkoop, echter ziekteverzuim a.g.v. migraine neemt mogelijk af en de daarmee gepaard gaande maatschappelijke kosten dus ook.

Potential total cost per year

Total cost	120,000,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Total cost

120,000,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

Off label use	No

Indication extension

Indication extension	No

Other information

There is currently no futher information available.